Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) Using the Zagreb Regimen as Simulated Rabies Post-exposure Prophylaxis in Healthy Adults in Thailand

Primary Objective:

To describe the immune response induced by VRVg-2 and Verorab vaccines at D14 and D35 when co-administered with Human Rabies Immunoglobulins (HRIG) at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects.

Secondary Objective:

Immunogenicity To describe the immune response induced by VRVg-2 and Verorab vaccines at D90 when co-administered with HRIG at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects.

Safety To describe the safety profile of VRVg-2 and Verorab vaccines when co administered with HRIG at D0, after each vaccination.

Study Overview

• Status: Completed
• Conditions: Rabies (Healthy Volunteers)
• Intervention / Treatment: Biological: Purified vero rabies vaccine - serum free; Biological: Human rabies immunoglobulins; Biological: Purified inactivated rabies vaccine

Detailed Description

The duration of each subject's participation in the study will be approximately 7 months (21 day-vaccination period followed by 6 months safety follow-up period).

• Study Type: Interventional
• Enrollment (Actual): 201
• Phase: Phase 3

Contacts and Locations

Study Locations

• Thailand
  • Bangkok, Thailand, 10330
    • Investigational site number 7640002
  • Bangkok, Thailand, 10400
    • Investigational site number 7640001
  • Bangkok, Thailand, 10700
    • Investigational site number 7640003

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion criteria :

• Aged ≥ 18 years on the day of inclusion
• Able to attend all scheduled visits and to comply with all study procedures
• Body Mass Index (BMI): 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2s

Exclusion criteria:

• Subject is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and 1 month after each vaccination. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile.
• Participation at the time of study enrollment or, planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
• Receipt of any vaccine in the 4 weeks (28 days) preceding the first study vaccination or planned receipt of any vaccine prior to Visit 7 (D90)
• Previous vaccination against rabies (in pre- or post-exposure regimen) with either the study vaccines or another vaccine
• Bite by, or exposure to a potentially rabid animal in the previous 6 months without post-exposure prophylaxis
• Receipt of immune globulins, blood or blood-derived products in the past 3 months
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• At high risk for rabies exposure
• Known systemic hypersensitivity to any of the study/control vaccine components or to human rabies immunoglobulin (HRIG), or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
• Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• Current alcohol or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
• Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0 C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
• Personal history of Guillain-Barré syndrome
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
• Receipt of chloroquine or hydroxychloroquine up to 2 months prior to the study or through to study until Visit 7

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: VRVg-2 + HRIG; VRVg-2 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21 + HRIG at D0	Biological: Purified vero rabies vaccine - serum free; Pharmaceutical form:freeze-dried - Route of administration: intramuscular; Other Names: VRVg-2; Biological: Human rabies immunoglobulins; Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular; Other Names: HRIG
Active Comparator: Group 2: Verorab + HRIG; Verorab 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21 + HRIG at D0	Biological: Human rabies immunoglobulins; Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular; Other Names: HRIG; Biological: Purified inactivated rabies vaccine; Pharmaceutical form:freeze-dried - Route of administration: intramuscular; Other Names: Verorab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants achieving rabies virus neutralizing antibody (RVNA) titer greater than or equal to (≥) 0.5 IU/mL	RVNA titers will be measured by rapid fluorescent focus inhibition test (RFFIT)	Day 14 (post-vaccination)
Percentage of participants achieving RVNA titer greater than or equal to (≥) 0.5 IU/mL	RVNA titers will be measured by RFFIT	Day 35 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification	RVNA titers will be measured by RFFIT - Lower limit of quantification for RFFIT assay is 0.2 IU/mL	Day 14 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification	RVNA titers will be measured by RFFIT - Lower limit of quantification for RFFIT assay is 0.2 IU/mL	Day 35 (post-vaccination)
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)	RVNA titers against rabies virus will be measured by RFFIT at Day 0 and Day 14 - RVNA ratios Day14/Day0 will be calculated	Day 14 (post-vaccination
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)	RVNA titers against rabies virus will be measured by RFFIT at Day 0 and Day 35 - RVNA ratios Day35/Day0 will be calculated	Day 35 (post-vaccination)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants reporting immediate adverse events (AEs)	Unsolicited (spontaneously reported) systematic AEs	Within 30 minutes post-vaccination
Percentage of participants reporting solicited injection site and systemic reactions	Solicited injection site reactions: - pain, erythema, and swelling in adults (aged ≥ 18 years) Solicited systemic reactions: - fever, headache, malaise and myalgia in adults (aged ≥ 18 years)	Within 7 days post-vaccination
Number of participants reporting unsolicited injection site AEs	Unsolicited injection site AEs	Within 28 days post-vaccination
Number of participants reporting unsolicited systemic AEs	Unsolicited systemic AEs	Between each vaccination and up to 28 days after the last vaccination
Number of participants reporting serious adverse events (SAEs)	SAEs, including adverse event of special interest (AESIs)	Up to 6 months after last vaccination
Percentage of participants achieving rabies virus neutralizing antibody (RVNA) titer greater than or equal to (≥) 0.5 IU/mL	RVNA titers will be measured by RFFIT	Day 90 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification	RVNA titers will be measured by RFFIT - Lower limit of quantification for RFFIT assay is 0.2 IU/mL	Day 90 (post-vaccination)
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)	RVNA titers against rabies virus will be measured by RFFIT at Day 0 and Day 90 - RVNA ratios Day90/Day0 will be calculated	Day 90 (post-vaccination)

Collaborators and Investigators

• Sponsor: Sanofi Pasteur, a Sanofi Company
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi Pasteur, a Sanofi Company

Study record dates

Study Major Dates

• Study Start (Actual): October 11, 2020
• Primary Completion (Actual): June 23, 2021
• Study Completion (Actual): June 23, 2021

Study Registration Dates

• First Submitted: October 12, 2020
• First Submitted That Met QC Criteria: October 13, 2020
• First Posted (Actual): October 20, 2020

Study Record Updates

• Last Update Posted (Actual): July 13, 2023
• Last Update Submitted That Met QC Criteria: July 11, 2023
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Rabies
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Mononegavirales Infections; Rhabdoviridae Infections; Rabies; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Vaccines; Immunoglobulins; Immunoglobulins, Intravenous
• Other Study ID Numbers: VRV00014; U1111-1238-1726 (Other Identifier: UTN)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No